Related Experiment Videos
Falciparum malaria semi-resistant to clindamycin
British Medical Journal
|April 5, 1975
Summary
Clindamycin monotherapy partially treated chloroquine-resistant malaria. Combination therapy with quinine and clindamycin showed promise but caused gastrointestinal side effects, warranting further study for malaria treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Tropical Medicine
Background:
- Chloroquine-resistant *falciparum* malaria remains a significant global health challenge.
- Alternative and combination therapies are crucial for effective malaria treatment.
- Clindamycin, an antibiotic, has been explored for its antimalarial potential.
Purpose of the Study:
- To evaluate the efficacy and toxicity of clindamycin monotherapy for chloroquine-resistant *falciparum* malaria.
- To assess the effectiveness of combination therapy using quinine and clindamycin.
- To investigate sequential therapy as a treatment option for relapsed malaria cases.
Main Methods:
- Adult patients with moderately ill chloroquine-resistant *falciparum* malaria were treated.
- Clindamycin was administered at 450 mg eight-hourly for three days as monotherapy.
- Combination therapy involved full or half dosage of quinine with clindamycin for three days.
Main Results:
- Clindamycin monotherapy cured 50% (5/10) of patients.
- Combination therapy with full-dose quinine and clindamycin achieved a 100% cure rate (4/4).
- Half dosage combination therapy cured 60% (3/5) of patients; both combinations caused gastrointestinal toxicity.
Conclusions:
- Clindamycin shows partial efficacy against chloroquine-resistant *falciparum* malaria.
- Quinine-clindamycin combination therapy is effective but associated with upper gastrointestinal toxicity.
- Sequential therapy was well-tolerated and may benefit patients with treatment relapses.